Kala Bio KALA
NASDAQ KALA
$0.38 -0.04 (-9.52%)
At close: Oct 2, 2026 · 4:00 PM EDT

Kala Bio (KALA) Gains from Sales and Divestitures (2018 - 2022)

Updated

Kala Bio (KALA) posted Gains from Sales and Divestitures of -$549,000 for FY2025.

Analysis

Kala Bio (KALA) Gains from Sales and Divestitures (2018 - 2022) Analysis & Trends

  • The FY2025 figure stands as the highest annual Gains from Sales and Divestitures since FY2022.
  • Business Quant data shows KALA's Gains from Sales and Divestitures at $47 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Kala Bio 5.81 Mn 5.81 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 47.00 Mn
Sep 30, 2018 -5,000.00
Mar 31, 2018 -4,000.00
API Access

Kala Bio Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=KALA&period=max&api_key=YOUR_API_KEY